Five healthy human leukocyte antigen-B8 (HLA-B8)-positive virus carriers were studied to investigate the CD8 / cytotoxic T lymphocyte (CTL) response to an HLA-B8-restricted peptide, RAKFKQLLQ, located in the Epstein-Barr virus (EBV) immediate-early trans-activator protein, BZLF1. Of the 5 virus carriers, 4 were infected with type A and 1 with type B EBV. Using limitingdilution analysis of peripheral blood mononuclear cells, a high RAKFKQLLQ-specific CTL precursor frequency was demonstrated after specific peptide or autologous lymphoblastoid cell line stimulation in both type A and type B EBV carriers. The RAKFKQLLQ-specific CTL precursor frequencies in all 5 persons were at least as dominant as those observed with two other EBV-associated, HLA-B8-restricted latent epitopes, FLRGRAYGL and QAKWRLQTL. These findings show that healthy virus carriers maintain a high frequency of BZLF1-specific memory T cells, potentially to control virus spread from lytically infected cells. [3]. The persistent replication of virus in epithelial cells is thought to be dependent EB1, and Z) in healthy virus carriers [7] and in the BHRF1 protein in acute IM [8]. BZLF1 protein is expressed early in on a continual supply of virus from permissively infected B cells infiltrating the mucosal epithelium [1, 4]. Two major the lytic cycle and is pivotal in the switch of EBV from the latent to the productive cycle [1, 7]. This protein therefore is subtypes of EBV, types A and B, have been identified that are differentiated within the BamHIWYH and HindIIIE regions of potentially a vital target for EBV-specific CTL surveillance, because lytically infected cells could be eliminated before the the EBV genome, encoding the latent antigens, Epstein-Barr nuclear antigens (EBNAs) 1-6, and latent membrane proteins release of mature virions. To investigate the potential relevance of the BZLF1 protein in immune surveillance, we compared (LMP) 1 and 2 [1]. The outgrowth in vivo of EBV-transformed B cells is most likely controlled by EBV-specific cytotoxic T the frequency of the CTL precursor (CTLp) to the BZLF1-associated epitope RAKFKQLLQ (RAK) in the peripheral lymphocytes (CTLs) that recognize multiple epitopes within these latent antigens [1, 5]. By contrast, the role of EBVblood of healthy virus carriers with the frequency of CTLp to two other well-characterized type A HLA-B8-restricted epitopes, FLRGRAYGL (FLR) and QAKWRLQTL (QAK), which are found in the latent EBV nuclear antigen 3 protein
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Epstein
Donor MS consistently did not respond to the type A-specific The memory CTL response to the BZLF1-associated epitope, epitopes FLR or QAK, either in the bulk CTL assay or LDA. The RAK, and the EBNA 3-associated epitopes, FLR and QAK, was T cell regression assay [10] showed that donor MS, in contrast to determined using a bulk CTL assay as previously described [9] .
donors BM, ISM, SP, and CR, did not have detectable memory T In brief, PBMC (2 1 10 6 /mL) were stimulated with g-irradiated cells to type A virus, but instead possessed a strong memory CTL (8000 rad) autologous type A or B lymphoblastoid cell lines response to a type B EBV epitope (unpublished data), confirming (LCLs), or peptide-coated PBMC (2000 rad). After 7 days, effector the type B status of donor MS. cell activity was assessed in standard 5-h 51 Cr-release assays using peptide-sensitized (10 mg/mL) phytohemagglutinin (PHA)-stimuResults lated blast cells as targets [9] . Figure 1 shows representative cytotoxicity patterns of poly-
The CTLp frequencies to the epitopes RAK, FLR, and QAK were quantified using limiting-dilution analysis (LDA) [9] . In brief, clonal CTLs generated from 5 HLA-B8-positive, EBV-sero- ). stim Å stimulated.
